Clinical trials in pediatric neuro-oncology: what is missing and how we can improve

Area of Science:

• Pediatric oncology
• Neuro-oncology
• Clinical trial design

Background:

• Brain tumors are the most common childhood solid tumors, with significant outcome disparities.
• High-grade gliomas have poor survival, while low-grade gliomas cause significant morbidity from tumor burden and treatment side effects.
• Current clinical trials often lack comprehensive endpoints for evaluating pediatric brain tumor therapies.

Purpose of the Study:

• To highlight the limitations of current clinical trial designs in pediatric brain tumor research.
• To advocate for the inclusion of broader endpoints beyond tumor response.
• To propose a more holistic approach to assessing therapeutic success.

Main Methods:

• Review of current clinical trial designs in pediatric brain tumor research.
• Identification of critical endpoints for comprehensive therapy assessment.
• Discussion on integrating quality of life and neurocognitive function into trial interpretations.

Main Results:

• Current trial designs frequently overlook crucial patient-centered outcomes.
• Tumor response alone provides an incomplete picture of therapeutic effectiveness.
• There is a need to incorporate quality of life, neurocognitive function, and neurofunctional deficits.

Conclusions:

• Clinical trials for pediatric brain tumors must expand their endpoint criteria.
• A comprehensive assessment requires evaluating tumor response alongside patient-reported outcomes and functional status.
• This approach will lead to more informed treatment decisions and improved long-term outcomes for children.